DFI6153.

Methods	STUDY DESIGN: Parallel group LOCATION, NUMBER OF CENTRES: USA, 66 centres DURATION OF STUDY: 6 weeks (2 week run‐in on FP 100mcg) CONCEALMENT OF ALLOCATION: Unclear COCHRANE QUALITY SCORE: B DESCRIBED AS RANDOMISED: Yes DESCRIBED AS DOUBLE BLIND: Yes METHOD OF RANDOMISATION WELL DESCRIBED/APPROPRIATE: Not reported METHOD OF BLINDING WELL DESCRIBED/APPROPRIATE: Not clear DESCRIPTION OF WITHDRAWALS/DROPOUTS: Not clear JADAD SCORE (5‐1): 2 TYPE OF ANALYSIS (AVAILABLE CASE/TREATMENT RECEIVED/ ITT): ITT COMPLIANCE: Not reported CONFOUNDERS: Not clear
Participants	N SCREENED: Not clear N RANDOMISED: 1145 N COMPLETED: Not clear M=not clear ; F= not clear MEDIAN AGE (range): Not clear BASELINE DETAILS: Not available INCLUSION CRITERIA: >12 years; history of persistent asthma (>6 months before screening); treatment with ICS for >1 month before screening; FEV1 >40% and <80% predicted. EXCLUSION: Not reported.
Interventions	1. Ciclesonide 100mcg BD 2. Ciclesonide 200mcg BD 3. Ciclesonide 400mcg BD 4. CIcliesonide 400mcg BD 5. Ciclesonide 800mcg BD 6. Placebo DELIVERY: CIC: DPI (CIC group 3 given via MDI) TREATMENT PERIOD: 6 weeks RESCUE: Salbutamol MDI CO‐INTERVENTIONS PERMITTED: % on ICS baseline: 100
Outcomes	FEV1; am PEF; rescue medication use; symptoms; nocturnal awakenings; safety
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment?	Unclear risk	B ‐ Unclear